Subsequently, an MEK inhibitor (MEKi), cobimetinib, was evaluated and approved for histiocytic neoplasms regardless of the mutational status based on a small phase II trial showing an 89% overall response rate (ORR) [3]. The gene discussed is MAP2K7; the disease is histiocytic neoplasm.